Immedica Pharma AB – FDA CRL

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Immedica Pharma AB concerning Biologics License Application (BLA) 761211 for AEB1102, a treatment for arginase 1 deficiency (ARG1-D). The FDA acknowledged the significant unmet medical need for this rare and serious condition but could not approve the application as submitted. Key deficiencies included the lack of established dose adjustment and monitoring parameters for plasma arginine necessary for safe and effective use. Crucially, the effectiveness of AEB1102 for traditional approval was not definitively demonstrated. While a pivotal trial showed a statistically significant reduction in plasma arginine, it failed to meet its key secondary clinical endpoints, and plasma arginine has not been validated as a surrogate endpoint predictive of clinical benefit.

To resolve these issues, the FDA recommends conducting a new clinical trial designed to assess clinical outcomes and validate plasma arginine and/or its metabolites as predictive of benefit, suggesting this could serve as a postmarketing confirmatory trial if the application pursues an accelerated approval pathway. Required actions also include updating prescribing information in structured product labeling (SPL) format, resubmitting the proposed proprietary name, and providing a comprehensive safety update. This safety update must incorporate all new nonclinical and clinical data, including detailed analyses of adverse events, comparisons to original application data, and an updated summary of worldwide safety experience.